Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisKeratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin conditionVEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.Expression of Angiogenic Factors in Psoriasis VulgarisAssociation of VEGF gene polymorphisms with advanced retinopathy of prematurity: a meta-analysis.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis.Psoriasis: advances in pathophysiology and management.Angiogenesis drives psoriasis pathogenesis.The role of angiogenesis in the pathogenesis of psoriasis.Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.Acitretin revisited in the era of biologics.How genetic variation affects patient response and outcome to therapy for psoriasis.Pharmacogenetics of psoriasis.Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy.Investigational VEGF antagonists for psoriasis.Pharmacogenetics of topical and systemic treatment of psoriasis.VEGF involvement in psoriasis.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C/A, -1512 Ins18, and +405 C/G Polymorphisms within the Vascular Endothelial Growth Factor Gene.Pharmacogenetic model of retinoic acid-induced dyslipidemia and insulin resistance.Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.Acitretin Use in Dermatology.The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.Association of psoriasis with the VEGF gene polymorphism in the northern Polish population.Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients
P2860
Q22305863-18DCA6AA-50A1-4474-B868-BED69E36498DQ26822766-4D6C9422-D8DE-497B-9876-5F20E2A73C9CQ33268240-C6A46074-60FA-423D-BC34-ECA5D3ABEB30Q33666312-8E3E81F7-9C34-48A7-BA70-5DD7F0D6BCA6Q34445200-BDC4BA37-A101-451D-9CD0-BEB7BF92C74CQ34620375-D2797E3E-02AF-447D-9896-F00302996224Q34800330-DB896F00-0A43-419D-A554-307CC907B1CCQ36995858-5B20EAF0-17A0-4E5D-921D-D5935E13A184Q37534974-E042964F-BBBB-428A-8DB4-1040AF1ABF0BQ37622941-DF4F297C-6861-4FDD-992E-50692327A77CQ37667504-D8C62AFB-001A-4367-9D46-A416FF1399F6Q37690746-91021FA4-8B6C-47CE-8FDF-BC9E17760DB6Q37722744-98EEBEBD-3751-4DD1-802E-6EBCCD1F1177Q37776735-41DEFED3-DC6F-4E9B-ABC4-3E49469BCCD7Q37803415-ACA127E7-5312-42E2-833B-0CB3EEEC040DQ37822759-A11A84C0-0D13-4655-A024-F19D37FAAF88Q37952328-22151980-1AD6-43C9-9DB6-3EF1A99E783BQ37956733-76C9679E-8383-4494-8AA5-12B50451A328Q38148599-7F6092EE-03DA-4015-AF8A-3C34CA614C02Q38648336-C8DF36C5-A7A0-43AF-AA2D-45F5D5C9712CQ38728552-BFE42CAB-D141-4AF2-A90E-BC5FDE5B4643Q39205065-04472115-6762-4411-896D-FEEB1D13A500Q39218034-39CD02FA-D5E2-4A28-9988-5B56F25A0807Q42087723-00E6A649-A7E9-4EA1-8F0C-63DCFE25A9B5Q43230869-9F8D1DF1-E901-4330-9978-7F007036DC3CQ46646221-23EC2EA7-E88E-491B-A2BE-6BE4BFD311ADQ47786696-94B51A38-3F83-4B93-9EBC-7C04DBE15D22Q48170767-78138AF1-0A61-4A82-957F-FD143B8ECC0FQ48280209-FB557BF3-C368-46C4-B9E8-43F843317056Q49793746-C4E0C197-D0A6-45C6-A6A4-74D1876EDFF3Q51430093-BF4BE85D-E939-4D02-86FD-8D746EDCB14CQ52802857-5EE342FB-75A5-4365-8103-503F65E77BFCQ54333710-E929F95C-F250-48B2-BF63-A1AC4BA4571BQ58765353-37178408-3A4D-47C0-98B9-779D035D1334
P2860
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Interaction between genetic co ...... d responsiveness in psoriasis.
@en
type
label
Interaction between genetic co ...... d responsiveness in psoriasis.
@en
prefLabel
Interaction between genetic co ...... d responsiveness in psoriasis.
@en
P2093
P50
P356
P1476
Interaction between genetic co ...... id responsiveness in psoriasis
@en
P2093
Angela M Summers
Darren J Plant
David A Fairhurst
Emanuela Campalani
Ian R Read
Michael J Detmar
P2888
P304
P356
10.1038/SJ.JID.5700096
P407
P577
2006-02-01T00:00:00Z